FDA OKs First Darunavir-Based Single-Tablet Treatment Regimen for HIV

Officials with the FDA have approved Janssen’s Symtuza for the treatment of HIV-1 infection, according to a press release.
 
Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) is the first and only complete darunavir-based single tablet regimen (STR) for the treatment of HIV-1 in treatment-naïve and certain virologically suppressed adults.
 
Cobicistat, emtricitabine, and tenofovir alafenamide are from Gilead Sciences, Inc.
 
The approval is based on data from two phase 3 studies, AMBER and EMERALD, which evaluated the safety and efficacy of Symtuza compared with a control regimen in adults with no prior antiretroviral (ARV) history and in virologically suppressed adults.
 
The AMBER trial compared treatment with Symtuza to darunavir/cobicistat (D/C) plus emtricitabine/tenofovir disoproxil fumarate (F/TDF). According to the data, similar viral suppression rates were demonstrated between darunavir-based STR versus the control and low virologic rates at 48 weeks. Additionally, Symtuza showed less bone loss and a significant improvement in markers of renal function versus the control. Overall, the treatment was well-tolerated in participants.
 
In the EMERALD study, Symtuza was evaluated in comparison with continuing treatment with a boosted protease inhibitor plus emtricitabine and TDF. According to the data, the trial found there were low virologic rates and high virologic suppression rates at week 48. Patients who switched to Symtuza demonstrated improvement in bone mineral density and a significant improvement in some markers of renal function versus the control. The safety profile was similar to that of those patients with no prior ARV treatment history.

Related Coverage: National Institutes of Health Grants $7.7 Million for HIV Research
 
“As clinicians, we may not always have the full picture of a patient’s health or their risk for developing resistance when making treatment decisions,” Joseph Eron, MD, professor of Medicine and director, Clinical Core, University of North Carolina Centers for AIDS Research, said in a press release. “In key phase 3 clinical trials, Symtuza successfully treated those who were starting therapy, as well as those who were stably suppressed on antiretroviral therapy – including patients with more complex treatment histories or previous virologic failure – demonstrating its potential as an important new treatment option for a wide variety of patients.”
 
The recommended dosage of Symtuza is 1 tablet taken once-daily with food, according to Janssen. Symtuza is not recommended in patients with creatinine clearance below 30 mL per minute or those with severe hepatic impairment.
 
According to the prescribing information, prior to or when initiating treatment with Symtuza, patients should be tested for hepatitis B virus (HBV) infection and renal function, which should be monitored as clinically appropriate during therapy.
 
Symtuza has a boxed warning regarding the risk of post-treatment acute exacerbation of HBV.
 
Reference
 
Janssen Announces US FDA Approval of Symtuza (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection [news release]. Janssen’s website. https://www.janssen.com/janssen-announces-us-fda-approval-symtuza-dcftaf-first-and-only-complete-darunavir-based-single-0. Accessed July 18, 2018. 


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Clinical data demonstrate continued virologic response rates in patients with HIV switching to Symtuza from boosted protease inhibitor-based regimens.
Two studies assessed prostate specific antigen (PSA) progression in patients treated with apalutamide (Erleada, Janssen) and the association between PSA doubling time and survival.
Data from two phase 3 studies showed that esketamine nasal spray demonstrated improvements in depressive symptoms for patients who did not respond to other antidepressant treatments.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$